Please login to the form below

Not currently logged in
Email:
Password:

Roche says Tecentriq "off to a good start"

Bladder cancer therapy drug seems set for rapid growth

Roche Basel Switzerland 

Roche's new bladder cancer therapy Tecentriq made $19m in sales in its first few weeks on the US market, helping the company beat first-half sales forecasts.

Tecentriq (atezolizumab) is the third drug in the fast-growing PD-1/PD-L1 inhibitor category to reach the market, and based on initial uptake seems set to follow the same rapid growth trajectory as its predecessors - Bristol-Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab).

The PD-L1 inhibitor was approved in May in the US as a treatment for locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed during or after platinum-based chemotherapy and is the first immuno-oncology drug to be approved in this setting. It is predicted to eventually become a $3bn product. 

Roche needs Tecentriq and other new launches such as AbbVie-partnered Venclexta (venetoclax) for chronic lymphocytic leukemia (CLL) to grow quickly as it starts to face the prospect of biosimilar competition for its big-selling antibody drugs.

Overall, revenues at the Swiss pharma group rose 4% to 25bn Swiss francs ($25.3bn) in the first six months of the year, with the pharma division up 4% to 19.46bn francs, which was a little higher than analyst consensus forecasts. 

Once again, cancer drugs drove the increase in the pharma division with its trio of therapies for HER2-positive breast cancer accounting for around 4.75bn francs. Strong gains for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) reinforced a 5% increase for HER2 stalwart Herceptin (trastuzumab) to 3.4bn francs.

Roche's top-selling drug MabThera/Rituxan (rituximab) - approved for several indications including non-Hodgkin's lymphoma and CLL - also managed a 4% increase to 3.7bn francs. 

Chief executive Severin Schwan highlighted the prospects for multiple sclerosis candidate Ocrevus (ocrelizumab), another potential blockbuster which was awarded a priority review by the FDA last month and could be effective in both relapsing/remitting and secondary progressive forms of MS.

Article by
Phil Taylor

21st July 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....